At the 48-week primary efficacy analysis ( re-intensification = failure ) , treatment success was 73 % in ATV/r arm and 85 % in ATV/r along with two NRTIs [ difference -12.1 % , 95 % confidence interval ( 95 % CI ) -27.8 to 2.1 ] .